The BRR service is based on streaming audio sent in compressed form over the internet and displayed as it arrives. You do not have to wait for the whole file to be downloaded before you can hear it, instead the media is sent in a continuous stream and is played immediately as it reaches your computer. Please note that during live broadcasts there can be a delay of approximately 1-2 minutes, depending on traffic through your Internet Service Provider.
Broadcaster: LIVING CELL TECHNOLOGIES LIMITED (ASX: LCT)
Broadcast Title: Living Cell Technologies Granted Diabetes Patent in the US
Broadcast Type: Audio stream
View the Audio stream for LIVING CELL TECHNOLOGIES LIMITED (ASX: LCT) by clicking on the following links.
Display in Windows Media Player
Display in MP3 Player or Transfer to Portable Podcast Device
Computers set up for access to the Internet, including at least a 28.8k modem and sufficient memory and hard disk space to run Windows Media Player or Real Player, should be able to run BRR media files.
About Boardroom Media
Boardroom.Media is a new breed of media company that's equal parts publisher, content producer, and streaming media technology business. With a strong footing in capital markets, professional services and asset management, the company has been a leading provider of multimedia communication solutions for corporate Australia for more than a decade.
About Living Cell Technologies Limited
Living Cell Technologies Limited (ASX:LCT) (OTCMKTS:LVCLY) is a New Zealand biotechnology company focused on discovering, developing and commercialising regenerative cell treatments which restore function using naturally occurring cells.
LCT’s lead product NTCELL(R) is an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells. After transplantation NTCELL functions as a biological factory producing neurotrophic factors to prevent and repair disease induced nerve degeneration.
The Phase I/IIa NTCELL clinical trial in New Zealand for the treatment of Parkinson’s disease met the primary endpoint of safety and showed encouraging clinical efficacy. A Phase IIb trial has been designed to further evaluate NTCELLs potential as a disease-modifying treatment for patients with Parkinson’s disease.
NTCELL has the potential to be used in a number of other central nervous system degenerative diseases such as Huntington’s, Alzheimer’s and motor neurone diseases.
Living Cell Technologies Limited